TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06205875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High dose serratus anterior plane block (2.4 mg/kg patient ideal body weight)
Description: The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% plus epinephrine solution will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% plus epinephrine solution will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound. In total a dose of 2.4mg/kg patient ideal body weight will be administered. There is a maximal dose of 200 mg adrenalized bupivacaine for patients with an ideal body weight of 83 kg or more.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low dose serratus anterior plane block (1.2mg/kg patient ideal body weight)
Description: The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCIA with morphine
Description: A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCIA with morphine
Description: A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
Study: NCT05852301

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, observational study only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, observational study only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, observational study only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, observational study only
Study: NCT05698264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
Description: Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
Description: Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
Study: NCT05245422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula - Partially hydrolyzed protein
Description: Partially hydrolyzed cow's milk protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula - Intact protein
Description: Intact cow's milk protein
Study: NCT05678062

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point-of-care ultrasound
Description: An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
Study: NCT04827043

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ultrasound guided quadratus lumborum block
Description: prospective randomized comparative study between Group (1) : quadratus lumborum block

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ultrasound guided thoracic paravertebral block
Description: PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
Study: NCT06184425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural Puncture Epidural technique using pencil-point 25G Whitacre needle
Description: - DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 25-gauge pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural Puncture Epidural technique using pencil-point 27G Whitacre needle
Description: - DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 27-gauage pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
Study: NCT06440031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaMaPi
Description: CaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service.
Study: NCT05764213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to Women & Pregnant and Postpartum People
Description: Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.
Study: NCT05360212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomy-based fitting (ABF)
Description: MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Fitting
Description: These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard fitting+ ABF
Description: Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
Study: NCT04553796

Intervention type: DEVICE
Intervention: fibroscan
Description: Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions

Intervention type: DEVICE
Intervention: fibroscan
Description: Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions

Intervention type: DEVICE
Intervention: fibroscan
Description: Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
Study: NCT06046937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monolaurin
Description: applied thinly twice a day
Study: NCT04539392

Intervention type: OTHER
Intervention: Questionnaires on sexuality
Description: Panel of questionnaires assessing sexuality, relationship satisfaction, and body image
Study: NCT06632886

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-Assisted Non-Contrast CT for Multi-Cancer Screening
Description: Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.
Study: NCT05211648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia Bracelet
Description: Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The optical signals at the wrist are recorded non-invasively by means by the Aktiia bracelet. The Blood Pressure measurements are further determined from these optical signals and are compared to weekly and monthly Blood Pressure averages measured manually by traditional Home Blood Pressure Monitoring.
Study: NCT05669235

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
Study: NCT05661370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dermloop Learn
Description: Educational Mobile Application with a library of digital patient-cases and written learning modules the user can access on 36 common skin lesions, both benign and malignant.
Study: NCT04740216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise therapy plus jaw device
Description: The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise therapy
Description: the control group performed 20-minute stretching exercises each time.
Study: NCT04145258

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo of aspirin
Description: Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo of aspirin
Description: Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)

Intervention type: DRUG
Group type: OTHER
Intervention: WHO TBM treatment
Description: 2 months of (R-H-Z-E) + 7 months of (R-H)
Study: NCT06046937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: applied thinly twice a day
Study: NCT05268172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-γ and CIK cells, Tcm cells or CAR T cells
Description: A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
Study: NCT05267951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop Stimulation
Description: Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Close-loop Stimulation
Description: Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Task Practice
Description: Exercise therapy consists of repeated functional hand and arm movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Task Practice
Description: Exercise therapy consists of repeated functional hand and arm movements
Study: NCT05295108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caring Connections
Description: peer-based letter writing social connectedness intervention to improve social health outcomes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: informational materials provided to educate on life domains that are important to social health
Study: NCT04988750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: Using the neuronavigator to precisely guide the ultrasound energy to brain tissues in real-time and intraoperatively.
Study: NCT04145258

Intervention type: DRUG
Group type: OTHER
Intervention: WHO TBM treatment
Description: 2 months of (R-H-Z-E) + 7 months of (R-H)

Intervention type: DRUG
Group type: OTHER
Intervention: Intensified TBM treatment
Description: 2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid

Intervention type: DRUG
Group type: OTHER
Intervention: Intensified TBM treatment
Description: 2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
Study: NCT05519189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Peri-anal infiltration of Ropivacaine
Study: NCT06138691

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ketamine Infusion plus RO DBT
Description: The participant will receive 4 weeks of 0.5mg/kg intravenous ketamine given over 40 minutes, as is routinely done in ketamine treatment and four months of RO DBT treatment.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ketamine Infusion plus RO DBT
Description: The participant will receive 4 weeks of 0.5mg/kg intravenous ketamine given over 40 minutes, as is routinely done in ketamine treatment and four months of RO DBT treatment.
Study: NCT06238284

Intervention type: OTHER
Intervention: no intervention
Description: Since it is a retrospective study, no intervention is needed.

Intervention type: OTHER
Intervention: no intervention
Description: Since it is a retrospective study, no intervention is needed.

Intervention type: OTHER
Intervention: no intervention
Description: Since it is a retrospective study, no intervention is needed.
Study: NCT05629130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: embolization with spherical microparticles embosphere
Description: embolization of affected joints with spherical microparticles embosphere
Study: NCT06080685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Character Strengths Intervention
Description: Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Cultivate your inner self + Loving-Kindness Meditation Session 4. Gratitude Letter + Three Good things Session 5. Conclusion Each session will consist of 1-hour, which will be delivered once a week for 5 weeks. Moreover, participants will be given homework which they will practice the rest of the week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Character Strengths Intervention
Description: Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Cultivate your inner self + Loving-Kindness Meditation Session 4. Gratitude Letter + Three Good things Session 5. Conclusion Each session will consist of 1-hour, which will be delivered once a week for 5 weeks. Moreover, participants will be given homework which they will practice the rest of the week.
Study: NCT05824169

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC101
Description: Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC101
Description: Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
Study: NCT05018650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Route 92 Medical Reperfusion System
Description: Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Route 92 Medical Reperfusion System
Description: Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.
Study: NCT05639192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asunercept
Description: Asunercept (APG101) will be administered once per week as an i.v. infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once per week as an i.v. infusion
Study: NCT02035917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locking plate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Locking plate
Study: NCT05729243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine is a nicotinic acetylcholine receptor partial agonist and is a natural health product approved by Health Canada. Cytisine has been used for a long time in Europe for smoking cessation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo identical in appearance to cytisine will be used
Study: NCT05938998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga; Support Group
Description: BEHAVIORAL: Group Exercise Sessions- Yoga. BEHAVIORAL: Social Support Sessions
Study: NCT06432530

Intervention type: OTHER
Intervention: C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.
Description: Patients' hematological parameters were recorded, and hematological inflammatory indexes (NLR: neutrophil/lymphocyte; MLR: monocyte/lymphocyte; PLR: platelet/lymphocyte; NLPR: neutrophil/(lymphocyte\*platelet); SII (neutrophil\*platelet/lymphocyte): systemic inflammatory index; SIRI (neutrophil\*monocyte/lymphocyte): systemic inflammatory response index; AISI (neutrophil\*platelet\*monocyte/lymphocyte): aggregate index of systemic inflammation. ) were derived from baseline CBC tests.

Intervention type: OTHER
Intervention: C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.
Description: Patients' hematological parameters were recorded, and hematological inflammatory indexes (NLR: neutrophil/lymphocyte; MLR: monocyte/lymphocyte; PLR: platelet/lymphocyte; NLPR: neutrophil/(lymphocyte\*platelet); SII (neutrophil\*platelet/lymphocyte): systemic inflammatory index; SIRI (neutrophil\*monocyte/lymphocyte): systemic inflammatory response index; AISI (neutrophil\*platelet\*monocyte/lymphocyte): aggregate index of systemic inflammation. ) were derived from baseline CBC tests.
Study: NCT04541875

Intervention type: OTHER
Intervention: MAR-Scale
Description: The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.

Intervention type: OTHER
Intervention: MAR-Scale
Description: The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.

Intervention type: OTHER
Intervention: MAR-Scale
Description: The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
Study: NCT06028295

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex Oil
Description: The study foresees the intake of 2 capsules per day during 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex Powder
Description: The study foresees the intake of 2 capsules per day during 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 2 capsules per day during 84 days
Study: NCT05528978

Intervention type: BEHAVIORAL
Intervention: Shambhavi Kriya
Description: The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony.
Study: NCT05238610

Intervention type: PROCEDURE
Intervention: PFO closure
Description: PFO-closure will be performed after 3-6 month of observation and monitoring for paroxysmal atrial fibrillation